Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis

Published Date:

04/28/2015

Source:

PubMed - NCBI

Authors:

Little KM, Pai M, Dowdy DW

External link

Original Article

There is growing concern that interferon-γ release assays (IGRAs) are being used off-label for the diagnosis of active tuberculosis (TB) disease in many high-burden settings, including India, where the background prevalence of latent TB infection is high. We analyzed the costs and consequences of using IGRAs for the diagnosis of active TB in India from the perspective of the Indian TB control sector.

Events

«

January 2019

»
S
M
T
W
T
F
S
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·

Projects

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

FlexDx-TB: A flexible, user-friendly model of...

We have developed a web-based model that allows decision-makers to input local epidemiological and economic values and receive...

Read More

TBM-KIDS (India)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More

Enhancing models of HIV,viral hepatitis,...

The goal of this five-year project is to assist the United States Centers for Disease Control and Prevention in their approach...

Read More